Posted by Michael Wonder on 23 Dec 2022
UCB announces FDA acceptance of BLA resubmission for bimekizumab
23 December 2022 - The FDA designated the BLA resubmission as ‘Class 2’ with a six month review period.
UCB today announced that the US FDA has accepted for review the biologics license application resubmission for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis.
